Forum for Science, Industry and Business

Study highlights massive benefits of HIV treatment in South Africa

04.12.2013

In nation hardest hit by HIV, antiretroviral therapy has saved millions of years of life

Antiretroviral therapy (ART) for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases.

The analysis suggests these dramatic benefits could be even greater if more aggressive HIV testing and treatment strategies are implemented.

"We hope that this study reminds stakeholders of the astounding efficacy of the global ART rollout while simultaneously invigorating efforts to redouble commitments toward expanding the availability of ART," said lead study author Michael D. April, MD, DPhil, of the San Antonio Uniformed Services Health Education Consortium.

South Africa's HIV epidemic is the largest in the world, with an estimated 5.6 million people infected in 2011, according to UNAIDS. Although about half of those infected are eligible for treatment with ART, based on current guidelines for when to start therapy, one-third of those eligible remain without treatment, despite progress in expanding access since ART was introduced in the country in 2004. In this study, researchers used a mathematical model based on real world data to quantify the direct impact of the rollout of ART on survival among HIV-infected patients.

The researchers estimated that substantial survival gains from ART have already been achieved in South Africa: 2.8 million years of life gained as of December 2011. These years of life already saved represent just 15.6 percent of the 17.9 million years of life that will be saved by 2030 among patients currently receiving ART, according to the researchers' analysis.

Notably, these estimates exclude those who might benefit from starting ART in the future but who are not yet receiving it, Dr. April said. Continued international investment in the global response to HIV, including the U.S. President's Plan for Emergency AIDS Relief (PEPFAR), will be required to maintain the gains already achieved and efficiently expand access to ART. "Policymakers have the power to magnify the future trajectory of survival gains further still by pursuing more aggressive HIV testing and treatment strategies," Dr. April noted. "Increased case identification, early ART initiation, and expanded treatment options might catapult our conservative survival projections even further."

Despite earlier political decisions to limit ART scale-up in South Africa, the country's aggregate survival benefit from ART during just eight years (2004-2011) is similar to the considerable benefit reported previously for the U.S. over 15 years (1989-2003), wrote Sten H. Vermund, MD, PhD, of Vanderbilt University in Nashville, in an accompanying editorial commentary.

"The magnitude of the benefit of South African ART-based programs is astounding," wrote Dr. Vermund, who noted his hope that the bipartisanship in the U.S. that has characterized support of PEPFAR, which has been instrumental in the fight against HIV in sub-Saharan Africa, "will continue to bolster this essential investment for the future of the African continent."

The findings underscore the need to maintain the successes of an effective ART delivery system that today provides treatment for 1.4 million HIV-infected South Africans who need it—and to build on these accomplishments, the study authors said. National surveys suggest that only half of South Africans have ever been tested for HIV; there are likely large numbers of people infected with HIV in the high prevalence country that have yet to be identified and linked to lifesaving care.

"Our results suggest that rather than a debate over continuation of current funding commitments for the global response to HIV, policymakers and researchers should be examining strategies to most effectively and efficiently expand HIV testing and treatment efforts, to help increase future potential survival gains," said study author Rochelle P. Walensky, MD, MPH, of Massachusetts General Hospital and Harvard Medical School.

Fast Facts

1. Researchers used a mathematical model based on real world data to quantify the direct impact of the rollout of antiretroviral therapy (ART) on survival among HIV-infected patients in South Africa.

2. ART has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030.

3. These conservative estimates exclude those who might benefit from ART in the future. More aggressive HIV testing and treatment strategies could save even more years of life, if supported by ongoing international efforts to combat HIV.

NOTE: For a copy of the study and related editorial, which are embargoed until 12:01 a.m. EST on Wednesday, Dec. 4, please contact Jerica Pitts at jpitts@pcipr.com or 312-558-1770.

Published continuously since 1904, The Journal of Infectious Diseases is the premier global journal for original research on infectious diseases. The editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. The journal is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases.

Die letzten 5 Focus-News des innovations-reports im Überblick:

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...